Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chattem Ban Antiperspirant Divestiture To Fund New OTC Acquisitions

This article was originally published in The Tan Sheet

Executive Summary

Chattem will use the bulk of proceeds from the Ban antiperspirant line divestiture to Andrew Jergens to fund OTC acquisitions better suited to its "niche" product portfolio, the company said Aug. 24.
Advertisement

Related Content

Ban Beautifully Smooth Antiperspirant Prevents Shaving Irritation – Jergens
Ban Beautifully Smooth Antiperspirant Prevents Shaving Irritation – Jergens
Ban Beautifully Smooth Antiperspirant Prevents Shaving Irritation – Jergens
P&G Pharma Asset Exchange For Bristol's Clairol Possible, Analyst Says
P&G Pharma Asset Exchange For Bristol's Clairol Possible, Analyst Says
Ban advertising
Chattem
Right Guard Xtreme Sport $61 Mil. Marketing Campaign Targets Young Men
Dove Antiperspirant Positioning Echoes Skin Sensitivity Of Soap
Dove Antiperspirant Positioning Echoes Skin Sensitivity Of Soap

Topics

Advertisement
UsernamePublicRestriction

Register

PS091587

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel